1. Managing Rare CKDs

3. Gaps in Role of Inflammation in Rare CKDs

4. IgA Nephropathy

5. Focal Segmental Glomerulosclerosis

6. Evolution of Understanding the Progressive Nature of Kidney Disease

7. Anti-Inflammatory Drugs in Nephrology?

8. Personalized Medicine Genes Involved in FSGS

9. Treatment Options for Patients With CKD

10. Bardoxolone Mechanism of Action

11. PHOENIX Study Bardoxolone in Patients With Rare CKDs

12. CARDINAL Study Bardoxolone in Patients With Alport Syndrome

13. Bardoxolone Phase 2 Results Improvement in eGFR

14. TSUBAKI Study (Japan) in Patients With Diabetic CKD

15. BEAM Study Increasing Proteinuria With Increasing eGFR at 52 Weeks

16. Increases in Urinary Protein Are Consistent With Increases in GFR and Not Injury

17. Sustained Increase in eGFR Following Withdrawal of Bardoxolone Insights From BEACON Study

18. Bardoxolone Change in Disease Pathophysiology?

19. Take-Home Messages

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)